Introduction {#s1}
============

Pre-existing human immunodeficiency virus (HIV) infections affect the immune system increasing the risk for development of Kaposi sarcoma (KS). Since the discovery of Kaposi sarcoma-associated herpesvirus (KSHV), also termed human herpesvirus 8 (HHV8), the tumor development and oncogenesis were associated with co-expression of different genes ([@B3]; [@B28]). KS is a common type of cancer associated with blood vessels and lymph nodes. Soon after the discovery of HIV-1, scientists discovered γ-herpesvirus in KS lesions ([@B8]). Now that the full KSHV genome has been sequenced, it fulfils Koch\'s modern postulates linking the KS cancer initiation to the oncogenic virus ([@B52]; [@B71]). KSHV is a key viral pathogen in cancer biology affecting humans and its discovery promoted clinical and epidemiological research into viral oncology ([@B8]). However, many questions remain unanswered due to the significant mortality and rapid morbidity of those affected by HIV-1 and KSHV ([@B47]; [@B57]; [@B15]; [@B26]).

In fact, KS was named after Dr. Moritz Kaposi, a prominent Hungarian dermatologist, who described KS as an 'idiopathic pigmented sarcoma of the skin\' in 1872 ([@B37]). The evolved gamma-herpesviruses have been classified into many subfamilies ([@B51]) and produce many viral gene products capable of subverting the normal cellular machinery through processes involving apoptosis, cell cycle progression, antiviral responses, and immune surveillance resulting in alterations in master cell signaling pathways to establish a persistent host infection. The double-stranded KSHV genome (124--174 kb) is enclosed in an icosahedral capsid composed of 162 capsomeres with many of its ORFs being conserved in alpha- and beta-herpesviruses, but absent from other herpesviruses.

The KSHV is closely related to the subfamily Rhadinoviridae (gamma-2-herpesviruses), which is also close to the Herpes virus saimiri (HVS); therefore, similarities between ORFs of KSHV and HVS may influence the pathogenesis of KS ([@B53]). The HVS genome exists as a stable non-integrated circular episome in altered human and simian T cells. A group of genes, ORF71, ORF72, and ORF73, are located at the right end of the L-DNA and are expressed as polycistronic mRNAs ([@B21]). Initial studies discerned that both KSHV and HVS ORF71 encode the anti-apoptotic FLICE inhibitory protein (vFLIP) ([@B60]), although HVS ORF71 is not mandatory for viral replication, transformation, or pathogenicity ([@B29]). ORF72 produces a v-Cyclin D homolog which is important for transformation of human T lymphocytes ([@B20]). However, the function of ORF73 has remained a mystery. Therefore, developing and conducting comprehensive exploratory experiments to clarify the role of ORF73 in KSHV pathology is important.

Typically, the phenotypic features of KS initially appear on the face, legs, or feet as painless red spots but, in severe cases, the lesions also appear in the lungs and digestive tract ([@B5]; [@B68]). KSHV is considered an oncogenic human virus ([@B43]). People with weak immune systems are more susceptible to HHV-8 infection (triggering KS development). Even with the availability of the anti-retroviral treatment \[HAART\], the prevalence of AIDS-associated KS has not declined significantly ([@B46]). Although KSHV infection is important for the onset of KS, additional factors must be present to allow the establishment of the lesions. The chance of infection is one in 100,000 among the general population, but only around one in 20 among HIV-infected individuals ([@B39]). The chance of acquiring the infection was one in three among HIV-infected individuals before the introduction of HAART ([@B4]; [@B25]). Epidemiological observations from incidence rates in endemic areas suggest that HIV-negative individuals with KSHV infections never develop KS due to the role of immunological host factors including immune-response genes and genetic polymorphisms of the inflammatory modulators ([@B11]; [@B27]; [@B16]).

KSHV infection of endothelial and/or hematopoietic progenitors ([@B13]) alter their morphology ([@B45]), growth rate, gene expression ([@B22]; [@B10]), and glucose metabolism ([@B12]), leading to development of KS. Antibody titers specific for KSHV correlate with its viral load. Among individuals with low viral load, antibody titer concentrations may be too low for current serological assays to identify them. Identification of circulating biomarkers in KSHV-associated disease may help in predicting clinical outcomes ([@B1]). Immune modulatory and evasion proteins of KSHV modulate cellular responses associated with complement activation, autophagy, IFN family signaling, chemokines, natural killer cells, and apoptosis ([@B41]). They are located in a region of the viral capsid that is rich in a protein known as tegument. Six tegument proteins have been identified: ORF21, ORF33, ORF45, ORF63, ORF64, ORF73 and ORF75. Among these, the roles of ORF63 and ORF64 in immune evasion have been elucidated ([@B70]; [@B30]). We focused on the identification of the role of ORF73 in KSHV. The ORF73 gene encodes the HHV-LANA1 viral proteins that have been linked with AIDS-associated KS, indicating an association between HIV and ORF73. For our computational study, we hypothesized that ORF-73 is a viral proliferation factor based on studies on KS and on its interactions with the host gene p53 ([@B66]). The importance of ORF-73 for cellular host apoptosis through the p53 signaling pathway and p53 is in order of ORF-73 which illustrates the molecular mechanism of this key biomarker associated with KS ([@B17]).

The variability in KS lesions observed in histopathological assays include spindle cell hemangiomas, cutaneous angiosarcomas, vascular leiomyomas, and fibrous histiocytomas ([@B33]). Endothelial biomarkers, such as CD31 and CD34, bcl-2, c-kit, Ki-67, and p53, have been used to distinguish nonvascular spindle sarcomas from angiosarcomas ([@B65]; [@B24]). Hence, investigating the HHV-latent associated nuclear antigen-1 (LANA-1) viral protein encoded by ORF-73 is important to identify markers for AIDS-associated KS. Also, studying its interactions may help in the development of preventive strategies and therapeutic options against KS. In this study, we used advanced bioinformatics tools and approaches to identify KS markers [**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}.

Materials and Methods {#s2}
=====================

Selection of Markers {#s2_1}
--------------------

We used publicly available databases including the National Centre for Biotechnology Information (NCBI), GeneCards ([@B31]) and UniProtKB ([@B59]) to identify potential markers of KS and selected the most specific ones using "Kaposi\'s sarcoma" as a keyword. Human protein markers were further ran through a BLAST search for homology sequences. We extracted ORF-73 sequences from the NCBI database search using the accession number AAC57158.1. These are the exact URLs of the searched databases we used to identify markers associated with KS : GeneCards <https://genecards.weizmann.ac.il/v3/index.php?path=/Search/keyword/kaposi%20sarcoma%20markers/0/20>; UniPortKB <https://www.uniprot.org/uniprot/?query=kaposi+sarcoma&sort=score>; and NCBI <https://www.ncbi.nlm.nih.gov/protein/?term=ORF-73%20kaposi%20sarcoma>).

Bioinformatics: Sequence Computational Analysis {#s2_2}
-----------------------------------------------

We used publicly available internet-based protein search tools and bioinformatics programs with default settings, unless otherwise stated in the text, for the analysis. We tested selected protein sequences to identify conserved domains from NCBI and BLAST algorithms, and we used the PSIPRED program to predict the secondary structure of proteins based on the conserved domain sequences. We further executed a position specific iterative BLAST (PSI-BLAST) search to build a PSSMs (position specific score matrix), which could predict the secondary structure of the input sequences ([@B42]) to predict secondary structures of the selected conserved domains based on multiple sequence alignment related proteins spanning a variety of organisms to reveal sequence regions containing the same, or similar, patterns of amino acids. We submitted the primary sequence of ORF-73 to FUGUE to show the sequence-structural homology by identifying distant sequence-structure homologues and alignments comparing amino acid insertions/deletions ([@B56]). We used BLASTp and PSI-BLAST (non-redundant protein databases) for pattern specific profiling ([@B6]).

Gene Ontology and Pathway Enrichment Analysis {#s2_3}
---------------------------------------------

We chose the ORF-73 target effector to perform a Gene Ontology (GO) search, is a hierarchical graph-based annotation system where the terms closer to the root describe more general information while those away from the root provide more specific information about a given GO category and all the GO terms associated with a protein sequence were obtained from the GO database. The KEGG network pathway enrichment analysis by collecting data of related genomes and their pathways associated with diseases ([@B67]) and we set a *P* value \<0.05 as the cut-off criterion.

Protein--Protein Interaction (PPI) Network Analysis {#s2_4}
---------------------------------------------------

We used the online Search Tool for the Retrieval of Interacting Genes (STRING) ([@B23]) and GeneMania (<https://genemania.org/>) to analyze interactions associated with KS among the proteins encoded by the DEGs. The two parts of GeneMania algorithm consists of an algorithm based on linear regression to calculate functional association from multiple networks from different data sources; and a label predicting gene function of composite network. We employed keywords such as---ORF73 to determine interacting partners. This was pursued using downstream regulator p53 as an apoptosis marker during pathogenesis in the host. Moreover, the marker protein was used for transient interaction study.

PPI Biochemical Analysis {#s2_5}
------------------------

We immobilized His-tag, GST-tag, or biotin-tag bait proteins to an affinity resin and incubated them with solution expressed proteins as prey proteins. We then captured the bound bait and pulled down the cell lysate flow through. Subsequently, we used mass spectrometry (MS) or Western blots to confirm interactions. Using this technique, we determined interacting protein partners of relevant proteins ([@B19]; [@B2]).

Results {#s3}
=======

Homology Search and KS Marker Identification {#s3_1}
--------------------------------------------

Annotations used to search for the KS-associated markers in the UniProtKB database quoted about 137 entries, which we then screened to find those with computationally annotated data. Search engine GeneCards reported about 369 KS markers with a relevance score. [**Table 1**](#T1){ref-type="table"} lists the markers with the top ten scores.

###### 

GeneCards and UniPortKB databases used to choose the top-most scored identities of markers associated with KS.

  GeneCard database                                                                                         
  ------------------------- ---------------- ------------------------------------------------ ------------- --------------
  1                         KRT15            Keratin 15                                       GC17M039675   1.58
  2                         OSM              Oncostatin M                                     GC22M030658   1.58
  3                         TAT              Tyrosine aminotransferase                        GC16M071599   1.27
  4                         MKI67            Marker of proliferation Ki-67                    GC10M129894   1.14
  5                         CD34             CD34 molecule                                    GC01M208057   1.11
  6                         PTX3             Pentraxin 3, long                                GC03P157154   1.09
  7                         PECAM1           Platelet/endothelial cell adhesion molecule 1    GC17M062399   1.01
  8                         FLI1             Fli-1 proto-oncogene, ETS transcription factor   GC11P128596   1.01
  9                         IFNA2            Interferon, alpha 2                              GC09M021374   1.01
  10                        ACTC1            Actin, alpha, cardiac muscle 1                   GC15M035080   0.99
  **Uniport KB database**                                                                                   
  **Sl. No**.               **Entry name**   **Protein name**                                 **Entry**     **Gen name**
  1                         MIR1_HHV8P       E3 ubiquitin-protein ligase MIR1                 P90495        K3
  2                         MIR2_HHV8P       E3 ubiquitin-protein ligase MIR2                 P90489        K5
  3                         GB_HHV8P         Envelope glycoprotein B                          F5HB81        gBORF8
  4                         ARBH_HHV8P       Apoptosis regulator Bcl-2 homolog                F5HGJ3        vBCL2 ORF16
  5                         SCAF_HHV8P       Capsid scaffolding protein                       Q2HRB6        ORF17
  6                         OX2V_HHV8P       OX-2 membrane glycoprotein homolog               P0C788        K14
  7                         GN_HHV8P         Envelope glycoprotein N                          F5HFQ0        gN ORF53
  8                         GM_HHV8P         Envelope glycoprotein M                          F5HDD0        gM ORF39
  9                         ORF45_HHV8P      Protein ORF45                                    F5HDE4        ORF45
  10                        VMI2_HHV8P       Viral macrophage inflammatory protein            Q98157        ORF K4
  11                        VIRF1_HHV8P      VIRF-1                                           F5HF68        vIRF-1
  12                        ICP27_HHV8P      mRNA export factor ICP27 homolog                 Q2HR75        ORF57
  13                        GH_HHV8P         Envelope glycoprotein H                          F5HAK9        gH ORF22
  14                        AN_HHV8P         Shutoff alkaline exonuclease                     Q2HR95        ORF37
  15                        LANA1_HHV8P      Protein LANA1                                    Q9QR71        LANA1 ORF73

We found61 ORF-73 marker homologous hits related to the family of human gamma herpes virus 8 with varied E-values. Out of these, we used only the most identical sequence (based on sequence identity was measured by matched by dividing the length of region aligned match), AAC57158.1, for our computational analyses. A search for proteins similar to the selected marker ORF-73 resulted in8 protein accessions (ORF21, ORF33, ORF45, ORF63, ORF64, and ORF75), and 2 CDS regions (accession numbers AAC57158.1 and AAC55944.1).

Domain Prediction and Structural Profile {#s3_2}
----------------------------------------

We looked for conserved domains in the marker protein ORF-73 based on hypothetical domain sequences using literature recapitulation NCBI\'s Conserve Domain Database (CDD). To identify potential marker roles at the molecular level, we focused on its predicted secondary structure. Therefore, we searched for hypothetical protein having conserved domain and used accession number AAC5744 of gi.1633572 in an NCBI domain search and found only one significant hypothetical conserved domain (PHA03169) with the same accessison number ([**Figure 1**](#f1){ref-type="fig"}). We then used PSIPRED to predict the secondary structure, noted the conserved domains ([**Figure 2**](#f2){ref-type="fig"}) and highlighted the regions with different markers to predict the secondary structures. FUGE interpretation consolidations of the sequence-structure comparison were based on distance homology, where the score for the amino acids matching the insertion/deletion (indels) detected were based on structures compared to the FUGE database of structural profiles and we calculated the compatibility scores of sequence alignment accordingly ([**Table 2**](#T2){ref-type="table"}).

![Conserved hypothetical protein domain of PHA03169 in reference to the ORF-73 of Human gamma herpesvirus 8,E-value 38e−18.](fgene-10-01376-g001){#f1}

![Overview of the ORF-73 secondary structure prediction. The predicted structural positions incorporate two feed-forward neural networks obtained from PSI-BLAST.](fgene-10-01376-g002){#f2}

###### 

Structure of Kaposi sarcoma marker ORF-73 predicted based on an environmental-specific substitution table and its structure-dependent gap penalties.

  Sl. No.   Profile Hit      PLEN   RAWS   RVN   ZSCORE
  --------- ---------------- ------ ------ ----- --------
  1         hs4blga          121    −755   247   24.21
  2         [hs2ap3a]{.ul}   191    215    8     17.29
  3         [hs2qiha]{.ul}   136    −822   10    16.57
  4         [hs2p03a]{.ul}   323    249    21    14.78
  5         [hs1i4da]{.ul}   188    157    33    14.61
  6         [hs4cgka]{.ul}   351    325    115   13.67
  7         [hs2eqbb]{.ul}   93     −880   5     13.53
  8         [hs1fxka]{.ul}   103    168    19    13.45
  9         [hs1owaa]{.ul}   156    166    6     13.28
  10        [hs4hpqc]{.ul}   396    −555   5     12.92

PLEN, Profile length; RAWS, Raw alignment score; RVN, (Raw score)-(Raw score for NULL model); ZSCORE, Z-score normalized by sequence divergence (evolutionary relationship associated with a score \>5.0 to the sequences are compared to each other); ZORI, Original Z-score (before normalization).

Using PSI-BLAST, we confined the search of HHV-latency-associated nuclear antigen homology to ORF-73 homologs. The DNA binding of viral protein associated with HHV-8 LANA sheltered 134 residues covering 12% of the sequence with 100% confidence based on the single highest scoring template of c4k2jB ([**Figures 3**](#f3){ref-type="fig"} and [**4**](#f4){ref-type="fig"}). 598 residues covering 51% could be modelled at \>90% confidence using multiple-templates. We submitted the top-ranking model of the protein (c4k2jB, 100.0% confidence) to the 3DLigandSite ([@B64]) server to predict potential binding sites. Based on PSI-BLAST homologues, the predicted disordered structures were checked using PSI-Pred ([@B35]) and DISO-Pred ([@B34]) for generating a hidden Markov model (HMM). The models were based on the alignment of the constructed 3D models between the known structure and the HMM of our sequence predicting the3-states---α-helix, β-strand or coil ("SS" indicates the predicted confidence; middle orange, yellow, and green indicate the confidence of prediction).

![Highest scored template c4k2jB chain B structure.](fgene-10-01376-g003){#f3}

![Decameric ring structure of KSHV HHV-LANA DNA binding domain with dimensions (X:40.909, Y:43.389, and Z:44.674).](fgene-10-01376-g004){#f4}

Gene Expression and Pathway Prediction {#s3_3}
--------------------------------------

The exclusive over-expression of HHV-8 LANA-1 in KS confirms significant sensitivity and specificity. The domain is conserved in the HHV-8 and ORF-73, suggesting its expression during viral latency and allowing it to interact with p53, thereby inducing the apoptosis pathway. The evidence from another study indicates abnormal expression of p53 in the nodular region and metastatic lesion of angiosarcomas (rather than in the primary lesion) ([@B69]). To account for this, the lead p53 in KS was taken with reference to the database for a herpes virus-associated infection model so as to understand the immune evasion with a detailed pathway demonstrating the dominant role of a p53 oncogene in KSHV- ([**Figure 5**](#f5){ref-type="fig"}). The tumor suppressor antigen p53 depends on cellular conditions inducing arrest of the cell growth and controlling cell division. This process inhibits cyclin-dependent kinases mediated by the expression of BAX and FAS antigens or by the repression of the Bcl-2expression ([@B36]). Addressing the markers involved in the cell-cycle arrest is important to understand the molecular evolution of KS and for work towards its eradication. We examined PPIs to explore the complex biochemical interactions and molecular functions of proteins of interest with cellular components, as reported in [**Table 3**](#T3){ref-type="table"}. [**Table 3**](#T3){ref-type="table"} also presents the functional enrichment of p53 including its biological process, molecular functions, and cellular components. The effector p53 is directly involved in the arrest of the G1/S cell-cycle progression from normal to cancerous cells ([@B9]). Analysis of PPI with STRING showed an enriched p-value of 1.31e−05 with respect to the network having significantly more interactions than expected with 11 nodes, 47 edges, an average node degree of 8.55 and an average local cluster coefficient of 0.919 ([**Figure 6**](#f6){ref-type="fig"}). The functions of the protein p53, a tumor protein, are associated with various expression levels during oncogenesis. GeneMania predicted various valuable functions of the query protein and interacting partners associated with it ([**Figure 7**](#f7){ref-type="fig"}).

![The Kaposi sarcoma-associated herpesvirus infection pathway from KEGG. Reference pathway highlighted using red box shows that LANA is associated with p53 signaling pathway which confirms the predictable role of the ORF-73 protein in the KS associate marker protein.](fgene-10-01376-g005){#f5}

###### 

Functional enrichment of p53.

  Biological process (GO)                                                                                                            
  --------------------------------------- ------------- ---------------------------------------------------------------- ----------- ----------
  1                                       GO:0016579    Protein deubiquitination                                         10 of 275   3.83e−15
  2                                       GO:0007249    I-kappaB kinase/NF-kappaB signaling                              8 of 70     3.83e−15
  3                                       GO:0035666    TRIF-dependent toll-like receptor signaling pathway              6 of 24     8.43e−13
  4                                       GO:0051092    Positive regulation of NF-kappaB transcription factor activity   5 of 2142   6.64e−11
  5                                       GO:0070423    Nucleotide-binding oligomerization domain                        5 of 27     4.65e−10
  Molecular function (GO)                                                                                                            
  1                                       GO:0031625    Ubiquitin protein ligase binding                                 5 of 311    4.44e−05
  2                                       GO:0042975    Peroxisome proliferator activated receptor binding               2 of 10     0.00062
  3                                       GO:0019899    Enzyme binding                                                   7 of 2197   0.0012
  4                                       GO:0042802    Identical protein binding                                        6 of 1754   0.0032
  5                                       GO:0032813    Tumor necrosis factor receptor superfamily binding               2 of 46     0.0052
  Cellular components (GO)                                                                                                           
  1                                       GO:0043657    Host cell                                                        4 of 29     2.76e−07
  2                                       GO:0030666    Endocytic vesicle membrane                                       5 of 152    2.90e−07
  3                                       GO:0098805    Whole membrane                                                   8 of 1554   3.85e−06
  4                                       GO:0012506    Vesicle membrane                                                 6 of 743    1.69e−05
  5                                       GO:0005741    Mitochondrial outer membrane                                     4 of 181    3.05e−05
  KEGG pathway                                                                                                                       
  1                                       hsa04668      TNF signaling pathway                                            4 of 108    1.27e−05
  2                                       hsa04064      NF-kappa B signaling pathway                                     4 of 93     1.27e−05
  3                                       hsa05160      Hepatitis C                                                      4 of 131    1.60e−05
  4                                       hsa04210      Apoptosis                                                        4 of 135    1.60e−05
  5                                       hsa05167      Kaposi\'s sarcoma-associated herpesvirus infection               4 of 183    3.53e−05
  Reactome pathways                                                                                                                  
  1                                       HSA-5357956   TNFR1-induced NFkappaB signaling pathway                         9 of 30     3.98e−21
  2                                       HSA-5357905   Regulation of TNFR1 signaling                                    9 of 32     3.98e−21
  3                                       HSA-5689880   Ub-specific processing proteases                                 10 of 202   1.94e−17
  4                                       HSA-6804757   Regulation of TP53 Degradation                                   7 of 35     2.30e−15
  5                                       HSA-5675482   Regulation of necroptotic cell death                             6 of 17     2.63e−14
  UniPort keywords                                                                                                                   
  1                                       KW-0832       Ubl conjugation                                                  9 of 2380   1.28e−05
  2                                       KW-0013       ADP-ribosylation                                                 4 of 100    1.28e−05
  3                                       KW-1017       Isopeptide bond                                                  7 of 1713   0.00017
  4                                       KW-0945       Host--virus interaction                                          4 of 432    0.00094
  5                                       KW-0963       Cytoplasm                                                        9 of 4972   0.0015
  PFAM Protein Domains                                                                                                               
  1                                       PF14560       Ubiquitin-like domain                                            4 of 14     3.12e−09
  2                                       PF11976       Ubiquitin-2 like Rad60 SUMO-like                                 4 of 21     6.44e−09
  3                                       PF00240       Ubiquitin family                                                 4 of 46     7.76e−08
  4                                       PF02201       SWIB/MDM2 domain                                                 2 of 5      2.86e−05
  5                                       PF00641       Zn-finger in Ran binding protein and others                      2 of 16     0.00017
  INTERPRO Protein Domains and Features                                                                                              
  1                                       IPR019956     Ubiquitin                                                        4 of 12     1.83e−09
  2                                       IPR019954     Ubiquitin conserved site                                         4 of 10     1.83e−09
  3                                       IPR000626     Ubiquitin domain                                                 4 of 57     3.14e−07
  4                                       IPR016495     p53 negative regulator Mdm2/Mdm4                                 2 of 2      1.46e−05
  5                                       IPR029071     Ubiquitin-like domain superfamily                                4 of 184    1.75e−05
  SMART Protein Domains                                                                                                              
  1                                       SM00213       Ubiquitin homologues                                             4 of 45     6.77e−08
  2                                       SM00005       DEATH domain, found in proteins involved in cell death           2 of 27     0.00035
  3                                       SM00184       Ring finger                                                      3 of 308    0.0012

![Protein--protein interactions (PPI) between cell arrest marker p53 of cancer cell and Ubiquitin Specific Peptidase 2 (USP2). TNF receptor-associated factor 2 (TRAF2), tumor necrosis factor receptor superfamily member 1A (TNFRSF1A), polyubiquitin-C (UBC), protein Mdm4, E3 ubiquitin-protein ligase Mdm2, ubiquitin-40S ribosomal protein S27a, polyubiquitin-B (UBB), NF-kappa-B essential modulator (IKBKG), receptor-interacting serine/threonine--protein kinase 1 (RIPK1), and Ubiquitin-60S ribosomal protein L40 (UBA52) play important roles in the regulation of cell survival and apoptosis.](fgene-10-01376-g006){#f6}

![**(A)** Tumor protein 53 (TP53) network analysis and **(B)** members of the complex pathway and genes with co-expression, co-localization, genetic interactions and specific functions.](fgene-10-01376-g007){#f7}

Pulldown Strategy and Protein Interaction Prediction for Biomarker Selection {#s3_4}
----------------------------------------------------------------------------

Pull-down assays serve as a complementary method to further validate the predicted interactions in a quantitative manner towards understanding their dissociation constants and relative bindings of proteins and their direct binding sites. However, this is beyond the scope of this study. We believe the following recommendations should be followed by researchers investigating transient protein interactions: First, determining the protein solubility is essential. If the prey protein is at a too-high concentration, it will not be sufficiently soluble. Second, shortening the time and adjusting buffer conditions of incubation help prevent prey protein degradation. Third, checking the prey protein with beads if bait protein is not bound should be done as a control. Fourth, conducting all assays at a constant temperature of 4 °C should be considered if a variation in Kd is found between repeated experiments.

The tumor suppressor antigen p53 depends on specific cellular conditions to induce arrest of cell growth and to control cell division ([@B48]; [@B9]).

Our network analysis (entry N00170, class nt06164) showed involvement of LANA and other effector markers in KS conditions and helped elucidate their mechanisms of action ([**Figure 8**](#f8){ref-type="fig"}, [**Table 4**](#T4){ref-type="table"}). Therefore, we suggest that ORF-73 is an important protein that may be a useful biomarker for AIDS-related KS. Studies have suggested a linkage between ORF-73 and host apoptosis through p53 signaling pathways ([@B61]), that could represent a molecular mechanism for the predicted markers associated with KS. Our study discovered KS-associated markers which trigger cancer. ORF-73 encodes LANA-1 virtual proteins of KSHV, linking them with AIDS-associated KS, by their interaction with several cellular processes which include cell apoptosis (through p53) and inhibition of downstream transcriptomic performance. The association between HIV and ORF73 can be inferred by these findings.

![Network map of KEGG for the selected KS protein marker LANA. Protein downstream effect in the cell cycle of disease progression with pooled effectors in cell cycle arrest at G1/S and KS activating mechanisms.](fgene-10-01376-g008){#f8}

###### 

Identities of associated markers, downstream signaling candidates, and linked pathways during Kaposi sarcoma pathogenesis.

  Sl. No   Entry    Description
  -------- -------- -----------------------------------------------------------------------------
  1        N00216   HGF-MET-RAS-ERK signaling pathway
  2        N00160   KSHV K1 to RAS-ERK signaling pathway
  3        N00188   IL1-IL1R-JNK signaling pathway
  4        N00189   KSHV K15 to JNK signaling pathway
  5        N00186   IL1-IL1R-p38 signaling pathway
  6        N00187   KSHV Kaposin B to p38 signaling pathway
  7        N00182   IGF-IGFR-PI3K-NFKB signaling pathway
  8        N00179   KSHV K1 to PI3K-NFKB signaling pathway
  9        N00030   EGF-EGFR-RAS-PI3K signaling pathway
  10       N00159   KSHV K1 to PI3K signaling pathway
  11       N00056   Wnt signaling pathway
  12       N00175   KSHV LANA to Wnt signaling pathway
  13       N00053   Cytokine-Jak-STAT signaling pathway
  14       N00181   KSHV vIL-6 to Jak-STAT signaling pathway
  15       N00147   EGF-EGFR-PLCG-calcineurin signaling pathway
  16       N00180   KSHV K1 to PLCG-calcineurin signaling pathway
  17       N00172   KSHV K15 to PLCG-calcineurin signaling pathway
  18       N00148   TLR3-IRF7 signaling pathway
  19       N00162   KSHV vIRF3 to TLR3-IRF7 signaling pathway
  20       N00163   KSHV KIE1/2 to TLR3-IRF7 signaling pathway
  21       N00149   TLR3-IRF3 signaling pathway
  22       N00161   KSHV vIRF1/2 to TLR3-IRF3 signaling pathway
  23       N00463   Alternative pathway of complement activation
  24       N00213   KSHV Kaposin to alternative pathway of complement activation
  25       N00150   Type I IFN signaling pathway
  26       N00261   KSHV vIRF2 to IFN signaling pathway
  27       N00151   TNF-NFKB signaling pathway
  28       N00174   KSHV vFLIP to TNF-NFKB signaling pathway
  29       N00173   KSHV K15 to TNF-NFKB signaling pathway
  30       N00171   KSHV vFLIP to NFKB signaling pathway
  31       N00152   CXCR-GNB/G-ERK signaling pathway
  32       N00157   KSHV vGPCR to GNB/G-ERK signaling pathway
  33       N00153   CCR/CXCR-GNB/G-PI3K-RAC signaling pathway
  34       N00462   KSHV vCCL1/2/3 to CCR signaling pathway
  35       N00212   KSHV vCCL2 to CCR signaling pathway
  36       N00178   KSHV vGPCR to GNB/G-PI3K-JNK signaling pathway
  37       N00154   CXCR-GNB/G-PI3K-AKT signaling pathway
  38       N00158   KSHV vGPCR to GNB/G-PI3K-AKT signaling pathway
  39       N00363   Antigen processing and presentation by MHC class I molecules
  40       N00184   KSHV MIR1/2 to antigen processing and presentation by MHC class I molecules
  41       N00185   KSHV MIR2 to cell surface molecule-endocytosis
  42       N00155   Autophagy-vesicle nucleation
  43       N00177   KSHV vBCL2 to autophagy-vesicle nucleation
  44       N00156   Autophagy-vesicle elongation
  45       N00176   KSHV vFLIP to autophagy-vesicle elongation
  46       N00066   MDM2-p21-Cell cycle G1/S
  47       N00167   KSHV vIRF1/3 to p21-cell cycle G1/S
  48       N00169   KSHV LANA to p21-cell cycle G1/S
  49       N00168   KSHV vCyclin to cell cycle G1/S
  50       N00170   KSHV LANA to cell cycle G1/S
  51       N00146   Crosstalk between extrinsic and intrinsic apoptotic pathways
  52       N00166   KSHV vFLIP to crosstalk between extrinsic and intrinsic apoptotic pathways
  53       N00164   KSHV vBCL2 to crosstalk between extrinsic and intrinsic apoptotic pathways
  54       N00165   KSHV vIAP to crosstalk between extrinsic and intrinsic apoptotic pathways

Discussion {#s4}
==========

Many viral genes are homologous to host cellular genes in KSHV ([@B58]). The PubMed, Google Scholar, and Scopus searches confirmed the key diagnostic markers for KS based on the available literature. Our computational study on them revealed their importance and evolutionary role in human cancer biology. LANA-1 imparts important immunogenic effects to KSHV, and it specifically interacts with many cellular pathways, including that of cell apoptosis (through its interaction with p53, and repression of downstream transcripts; see [**Table 4**](#T4){ref-type="table"}). This induces oncogenesis by targeting the protein-E2F transcriptional regulatory pathway ([@B49]). The protein homologues identified through our search were structurally different from each other. Therefore, we analyzed selected proteins and compared them using homology searches for the selected domains to prove interactions with other host proteins that trigger and induce cancer in individuals with immunosuppression ([@B38]). Hyper mutation and conserved structural sequence similarities help to maintain key aspects of secondary and tertiary structures, which were consistent with the computational analyses in our study ([@B32]). [**Figure 5**](#f5){ref-type="fig"} shows the KSHV infection pathway from KEGG. We highlighted the reference pathway using a red box that shows that LANA is associated with the p53 signaling pathway. A BLAST homology search confirmed an ORF-73 marker interaction during herpesvirus pathogenesis. The results of STRING and KEGG searches suggested ORF-73 interacts with the host p53.

ORF-73 is not the only protein marker implicated in KS pathology, but much about it remains unknown. It is used as a marker for KSHV; especially, its protein folding and motifs are important for the marker assessment observed in the pattern of structural domains in the selected sequence analyzed with PSI-PRED. The pathogenic interactions in the network-based analysis between LANA and the host p53 suggest that LANA was confirmed by STRING and FUGUE tools. The predicted sequence motifs give detailed interactions that are conserved in the subfamilies of the herpesviruses as discussed in detail on the KEGG pathway with notable mechanisms described in the literature ([@B54]; [@B14]; [@B55]; [@B44]). However, the markers associated with KS need to be incorporated into comprehensive clinical cohort studies, designed using differential protein purification techniques and evidence-based knowledge on protein interactions with bait proteins to develop practical medical applications in the future.

Many PPIs have been elucidated using pull-down assays to map the genomes of many organisms, such as yeast ([@B62]), *Escherichia coli* ([@B2]) *Caenorhabditis elegans* ([@B50]).

Like all other herpesviruses, KSHV displays latency and a lytic life cycle replication that are characteristic of some viral gene expressions. The genes LANA, v-FLIP, v-cyclin, and Kaposins A, B, and C for latency facilitate the establishment of life in its host and survival against host immune mechanisms. During latency, proteins expressed as K1, K15, vIL6, vGPCR, vIRFs, and vCCLs participate in inflammatory and angiogenic processes evident in KS lesions. Many other lytic and latent viral proteins are involved in the transformation of KSHV host cells into malignant cells. Also, Bcl-2 is one of the major KS progression factors, and TP53 and c-myc have a role in the progression of disease. KS pathology is interconnected with immune modulation effects such as cell cycle arrest in the host cell, which is required for pathogenic conditions and is mitigated by modulating key factors such as LANA.

Likewise, measuring the expression level and identifying the function of the encoded protein products is important to understand the pathogenesis of KS. We used a methodology similar to that in co-immunoprecipitation (Co-IP) experiments because of our ligand\'s affinity to capture the strongest interacting proteins ([@B40]). MS identifies subunits and helps explore the structural information associated with the protein of interest ([@B7]). Dynamic PPI machines assemble or disassemble the ever-changing inter-, intra-, and extracellular influx cues as a preliminary step towards understanding the structure of proteins and to determine their functions to identify the relevant pathways of interacting proteins ([@B19]; [@B63]; [@B18]). The role and important reason to select ORF-73 in the study is that encoding LANA protein distinct domain induces a putative nuclear localization signal (NLS), which product shown interacting with many co-cellular p53, pRb, and ATF4/CREB2. LANA also modulates transcriptional activity of HIV-1 long terminal repeat and to understand the how ORF-73 appears to prevent activity of KS-associated genes was new to know to make preventive strategy ([@B53]). Our findings may help researchers planning cancer prevention strategies, but we used common computational analyses alone, and future studies with expression and interaction analyses should be used to confirm our results and generate treatment options for KS.

Conclusion {#s5}
==========

Our computational studies found that ORF-73 is involved in host apoptosis through p53 signaling pathways and is a key marker associated for Kaposi Sarcoma. This study also identified potential KS-associated genes which are reported to trigger cancer and suggested mechanisms of interaction that may help researcher developing prevention strategies.
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Flow chart showing the methodology for choosing selective markers for downstream analyses to develop a PPI network.
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